Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial. Article uri icon

Overview

authors

  • Wei, Andrew H
  • Roboz, Gail J
  • Dombret, Herve
  • Dohner, Hartmut
  • Schuh, Andre C
  • Montesinos, Pau
  • Selleslag, Dominik
  • Bondarenko, Sergey N
  • Prebet, Thomas
  • Lai, Yinzhi
  • Skikne, Barry
  • Beach, C L
  • Ravandi, Farhad

publication date

  • October 1, 2023

Research

keywords

  • Azacitidine
  • Leukemia, Myeloid, Acute

Identity

PubMed Central ID

  • PMC10542842

Scopus Document Identifier

  • 85174080407

Digital Object Identifier (DOI)

  • 10.3324/haematol.2022.282296

PubMed ID

  • 36951156

Additional Document Info

volume

  • 108

issue

  • 10